Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions. Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-24 8:26 AM EDT | Red Light Holland Corp.
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, today highlights recent U.S. federal policy developments supporting psychedelic research and outlines the potential implications for the sector and the Company. Recent announcements by U.S. President Donald Trump include an exec
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-04-23 7:30 AM EDT | Psyched Wellness Ltd.
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption c
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-23 7:00 AM EDT | Optimi Health Corp.
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Numinus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD. The Order directs the FDA to prioritize review of psychedelics with Breakthrough Therapy designation, establishes new investigational acces
2026-04-20 8:30 AM EDT | Numinus Wellness Inc.
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington Second psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks 69% of participants fell below clinical thresholds for anxiety and depression after second treatment Research builds on prior studies utilizing Filament's botanica
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-20 7:30 AM EDT | Red Light Holland Corp.
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken ini
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 6:00 AM EDT | Optimi Health Corp.
Optimi Health startet Ibogaine-Initiative, da US-Executive Order einen Weg für psychedelische Arzneimittelprodukte signalisiert
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. April 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein kommerziell tätiger pharmazeutischer Hersteller regulierter psychedelischer Arzneimittelprodukte, gab heute den Start seiner Ibogaine-Initiative bekannt. Ziel des Programms ist es, die nach GMP lizenzierte Plattform des Unternehmens mit Health-Canada-Zulassung auf die Herstellung und Lieferung von Ibogaine auszuwe
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 2:00 AM EDT | Optimi Health Corp.
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global cl
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-07 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the Carhart-Harris Lab ("CHL") at the University of California, San Francisco ("UCSF") by providing instructions on how to participate in the CHL Global Psychedelic Study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate us
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-04-01 9:20 AM EDT | Red Light Holland Corp.
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one o
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-03-27 7:30 AM EDT | Neural Therapeutics Inc.
Numinus Wellness Provides Update Regarding Listing Status
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the Toronto Stock Exchange ("TSX"). As previously disclosed in the Company's management information circular dated July 29,
2026-03-24 5:00 PM EDT | Numinus Wellness Inc.
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to the joint press release dated March 10, 2026, the Supreme Court of British Columbia issued an interim order (the "Interim Order") in connection with the previously announced acquisition by Red Light of all the issued and outstandin
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-23 8:15 AM EDT | Red Light Holland Corp.
Psyched Wellness Announces Closing of Private Placement and Shares for Debt Transaction and Resignation of a Director
Toronto, Ontario--(Newsfile Corp. - March 20, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces the closing of (i) the first tranche of its non-brokered private placement (the "Offering") for gross proceeds of C$859,653.47, led by Gotham Green Fund III, L.P. and Gotham Green Fund III (Q), L.P. (together with the
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-03-20 9:16 AM EDT | Psyched Wellness Ltd.
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Li
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-18 8:15 AM EDT | Red Light Holland Corp.
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed wi
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-03-16 7:00 AM EDT | Optimi Health Corp.
Numinus Wellness Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update. Corporate Update Over the past year, Numinus has undertaken a strategic transformation to streamline its operations and focus on its core
2026-03-13 5:00 PM EDT | Numinus Wellness Inc.
Psyched Wellness Announces Private Placement for Proceeds of up to C$1,719,306.94
Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is excited to announce that it has entered into a non-binding memorandum of terms (the "Term Sheet") with Gotham Green Fund III, L.P. and Gotham Green Fund III (Q), L.P. (together,
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-03-11 8:54 AM EDT | Psyched Wellness Ltd.
RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-11 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-03-10 4:40 PM EDT | Red Light Holland Corp.
Numinus Wellness Advises of a Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous auditor, Horizon Assurance LLP ("Horizon") no longer serves as the Company's auditor, with PKF Antares Professional Corpora
2026-03-03 5:00 PM EST | Numinus Wellness Inc.